The nuclear LIM-only protein 4 (LMO4) is upregulated in breast cancer, especially estrogen receptor-negative tumors, and its overexpression in mice leads to hyperplasia and tumor formation. Here, we show that deletion of LMO4 in the mammary glands of mice leads to impaired lobuloalveolar development due to decreased epithelial cell proliferation. With the goal of discovering potential LMO4-target genes, we also developed a conditional expression system in MCF-7 cells for both LMO4 and a dominant negative (DN) form of its co-regulator, cofactor of LIM domains (Clim/Ldb/Nli). We then used DNA microarrays to identify genes responsive to LMO4 and DN-Clim upregulation. One of the genes common to both data sets was bone morphogenic protein 7 (BMP7), whose expression is also significantly correlated with LMO4 transcript levels in a large dataset of human breast cancers, suggesting that BMP7 is a bona fide target gene of LMO4 in breast cancer. Inhibition of BMP7 partially blocks the effects of LMO4 on apoptosis, indicating that BMP7 mediates at least some functions of LMO4. Gene transfer studies show that LMO4 regulates the BMP7 promoter, and chromatin immunoprecipitation studies show that LMO4 and its cofactor Clim2 are recruited to the BMP7 promoter. Furthermore, we demonstrate that HDAC2 recruitment to the BMP7 promoter is inhibited by upregulation of LMO4 and that HDAC2 knockdown upregulates the promoter. These studies suggest a novel mechanism of action for LMO4: LMO4, Clim2 and HDAC2 are part of a transcriptional complex, and increased LMO4 levels can disrupt the complex, leading to decreased HDAC2 recruitment and increased promoter activity.
Introduction
Lim-only protein 4 (LMO4) belongs to a family of four mammalian nuclear LMOs characterized by the presence of two tandem LIM domains and no other functional domains (Bach, 2000) . LIM domains mediate protein-protein interactions, and all nuclear LMOs bind with high affinity to a transcriptional cofactor of LIM domains (Clim)/LIM domain binding protein (Ldb)/ Nuclear LIM interactors (Nli), which enhance transactivation by LIM homeodomain factors and some other DNA-binding proteins (Bach, 2000) . LMOs are proposed to function as transcriptional activators by recruiting Clims to DNA-binding proteins. LMOs can also feedback inhibit LIM homeodomain function by displacing Clim from LIM homeodomain proteins (Milan et al., 1998) . Recently, chromatin-modifying transcriptional cofactors, including HDACs have been identified as LMO4 interactors (Singh et al., 2005) .
LMOs play critical roles in distinct pathways of mammalian development and deregulation of their expression is linked to oncogenesis (Rabbitts et al., 1999) . LMO4 has been implicated in the cause or progression of breast cancers (Sum et al., 2005b) , squamous cell carcinomas of oral cavity (Mizunuma et al., 2003) and primary prostate cancers (Mousses et al., 2002) . The LMO4 gene is most highly expressed in mammary epithelial cells during midpregnancy (Wang et al., 2004) , a stage of active proliferation and invasion; interference with the protein (Wang et al., 2004) or deletion of the gene (Sum et al., 2005c) leads to impaired lobuloalveolar development of the mammary gland. LMO4 is overexpressed in over half of primary breast cancers and its expression is associated with a worse prognosis (Visvader et al., 2001; Sum et al., 2005b) . In addition, overexpression of LMO4 in the mammary gland of mice leads to hyperplasia and intraepithelial neoplasia (Sum et al., 2005b) . Furthermore, the LMO4 gene is activated by heregulin (Wang et al., 2004) and is overexpressed in Her2-mediated tumors (Landis et al., 2005) . Together, these observations demonstrate that LMO4 has critical functions in mammary epithelial cells.
While recent studies indicate that LMO4 promotes both normal development and tumor formation in the mammary gland, the molecular mechanisms underlying these effects remain unknown. In the present study, we identify bone morphogenic protein 7 (BMP7) as a target gene of LMO4 in breast cancer cells. We show that LMO4 associates with the BMP7 promoter and that alterations in the levels of LMO4 can regulate the recruitment of histone deacetylase HDAC2 to this promoter. Our studies have identified a novel transcriptional mechanism for LMO4 in which it activates transcription by decreasing recruitment of HDAC2 to the BMP7 promoter.
Results
Deletion of LMO4 causes decreased proliferation of mammary epithelial cells and impaired lobuloalveolar development LMO4 knockout mice die during embryogenesis or at birth (Hahm et al., 2004; Lee et al., 2005; Sum et al., 2005c) , precluding their use for studying the role of LMO4 in postnatal mammary gland development. We therefore interbred floxed LMO4 mice (Lee et al., 2005) with whey acidic protein (WAP)-Cre (Wagner et al., 1997) and mouse mammary tumor virus (MMTV)-Cre (Wagner et al., 1997 ) transgenic mice to achieve two types of Cre recombinase-mediated deletion of the LMO4 gene within mammary glands of mice (Supplementary Figure S1 ). Whole-mount and histological analyses were used to study the effect of LMO4 deletion on mammary gland development. Lobuloalveolar structures of WAP-Cre-LMO4 fl/fl mammary glands were decreased at days 13.5 and 17.5 of pregnancy, and at the first day of lactation (Figure 1a ). MMTV-Cre-LMO4 fl/fl mice showed striking impairment of lobuloalveolar development as early as day 5.5 of pregnancy (Figure 1b, top panels) . A decrease in ductular growth was also observed in 3-week-old MMTV-Cre-LMO4 fl/fl virgin mice (Supplementary Figure S2) . Consistent with impaired lobuloalveolar development, pups nursed by LMO4 knockout mothers show significantly decreased weight gain (Supplementary Figure S3) . Together, these studies indicate that LMO4 is a modulator of mammary gland development.
To determine the cause of decreased lobuloalveolar development in LMO4 knockout mice, we investigated proliferation of mammary epithelial cells with Ki67 immunostaining. In the normal mammary gland, expression of the proliferation marker Ki67 peaks in midpregnancy and by lactation day 1 there are few positive cells. Mammary epithelial cell proliferation was reduced by about 50% at pregnancy days 13.5 and 17.5 in both MMTV-Cre-LMO4
fl/fl and WAP-Cre-LMO4
fl/fl mice ( Figure 1c and d). While we found an increase in apoptosis of mammary epithelial cells at day 13.5 in WAP-Cre-LMO4 fl/fl mice (data not shown), apoptosis was not increased in the MMTV-Cre-LMO4 fl/fl mice, leading us to conclude that decreased epithelial cell proliferation is the major cause of decreased lobuloalveolar development in LMO4 knockout mice. These data add to previous studies (Wang et al., 2004; Sum et al., 2005c) implicating the LMO4 gene in lobuloalveolar development, by demonstrating consistent phenotypes in two types of mammary gland knockouts and by showing that LMO4 acts as early as day 5.5 in the pregnant mammary gland.
LMO4 increases apoptosis in MCF-7 breast cancer cells
To start investigating the effect of LMO4 in breast cancer, we selected the human MCF-7 breast cancer cell line for establishing an inducible LMO4 expression system; MCF-7 cells have low LMO4 levels (Wang et al., 2004) . We used the Tet-off system to establish several distinct MCF-7 cell clones, referred to as MCF7-LMO4-TetOff cells, in which the expression of Myctagged LMO4 was repressed by the presence of doxycycline in the medium (Figure 2a) . The induced LMO4 level is comparable to the LMO4 expression level found in T47D breast cancer cells (data not shown). We first characterized the effect of LMO4 on proliferation, and found no significant effect of LMO4 upregulation on cell numbers (data not shown). We then investigated whether expression of LMO4 affected apoptosis in MCF-7 cells. Removal of doxycycline significantly increased apoptosis in the MCF7-LMO4-TetOff cells, whereas no effect was observed in vector-transfected cells (Figure 2b , left panel). In time-course experiments, LMO4 increased apoptosis in a time-dependent manner ( Figure 2b , right panel). Consistent with results from the apoptosis assay, FACS analysis detected a moderate increase in Annexin V staining, as well as more Annexin V-positive dead cells, in the absence of doxycycline (increased LMO4) than in the presence of doxycycline (low LMO4) (Figure 2c ). In addition, elevated expression of LMO4 increased the amount of cleaved caspase-7 as detected by western blotting with antibodies against both uncleaved and cleaved caspase-7 (Figure 2d , left panel). When MCF7-LMO4-TetOff cells were treated with the general caspase inhibitor Z-VAD-FMZ, LMO4 was incapable of inducing apoptosis, indicating that the process was caspase-dependent ( Figure 2d , right panel). The effect of LMO4 on apoptosis is not limited to MCF7 cells because similar increase in apoptosis was observed in human mammary epithelial cells (HMEC) transduced with retroviruses expressing LMO4 (Supplementary Figure S4 ). Together, these results show that LMO4 upregulation can induce caspase-dependent apoptosis in breast cancer cells.
Identification of LMO4-responsive genes
To identify LMO4-responsive genes, we profiled gene expression in three distinct MCF7-LMO4-TetOff cell clones in the presence (low LMO4) and absence (increased LMO4) of doxycycline (Figure 2a) . Using a cutoff Po0.01 (Baldi and Long, 2001) , we found that out of nearly 18 000 expressed probe sets only 111 and 98 were upregulated and downregulated, respectively (Figure 3a ). Among the differentially expressed genes, apoptosis is the only Gene Ontology biological process category that is significantly enriched (P ¼ 0.006; Dennis LMO proteins lack DNA-binding domains and regulate gene expression by at least two different mechanisms (Bach, 2000) . Figure S5) . The DN-Clim protein is composed of the C-terminal domain responsible for interactions with LIM domains and other DNA-binding proteins, but lacks the N terminus, which is critical for dimerization and transactivation (Jurata et al., 1998) . Therefore, DN-Clim blocks productive interactions between LMO4 and Clims.
We then performed microarray analysis in the MCF7-DN-Clim-TetOff cells, comparing expression profiles under control conditions with cells expressing the DNClim ( Figure 3a) ; we also found an enrichment of the apoptosis category (P ¼ 0.049) in the differentially expressed genes. Interestingly, three genes were significantly differentially expressed (Po0.01) by both LMO4 and DN-Clim: BMP7, GAS5 and LIN7A. All three genes were altered in the same direction in both cell lines, suggesting that in MCF-7 cells, LMO4 upregulation functions by disrupting Clim-containing transcription A2  A3  A4  A5  A6  B1  B2  B3  B4  B5  B6  B7  B8  B9  B10  B11  B12  B13  B14  B15  B16  L1  L2  L3  L4  L5  L6  L7  L8  L9  L10  L11  L12  L13  L14  L15  L16  L17  L18  L19  L20  L21  L22  L23  L24  L25  L26 LMO4 and regulation of BMP7 gene expression N Wang et al complexes on these responsive genes. This is similar to the Drosophila wing where LMO4 upregulation and DN-Clim have similar effects (Milan et al., 1998) . We used quantitative real-time PCR to validate the microarray results for several LMO4-responsive genes, including BMP7 (Figure 3b) . Doxycycline had no effect on the expression of these genes in cell clones transfected with vector alone (not shown). For reference, complete lists of differentially expressed genes by LMO4 and DNClim with cutoff Po0.05 are provided (Supplementary Figures S6 and S7, respectively) . All primary microarray data are accessible at www.ncbi.nlm.nih.gov/geo (GSE7382). We selected BMP7 for further study because BMP7 mediates epithelial-mesenchymal signaling (Dean et al., 2004) , and epithelial cell apoptosis and proliferation in several different organ systems (Luo et al., 1995; Monroe et al., 2000) . Consistent with these observations, we found that BMP7 can decrease proliferation and increase apoptosis of normal and cancerous mammary epithelial cells (Supplementary Figure S8) . In addition, follistatin, an inhibitor of the BMP5-7 subclass (Augsburger et al., 1999) , decreased LMO4-induced apoptosis of MCF7 cells (Figure 3c ), indicating that LMO4-stimulated apoptosis is at least in part mediated by BMPs. Estradiol has been shown to downregulate both BMP7 and its receptor ActRIIB in a variety of hormone-responsive epithelial cells (Kusumegi et al., 2004) . In fact, estradiol inhibits apoptosis in epithelial cells of reproductive epithelia by suppressing BMP7 signaling (Monroe et al., 2000) . Interestingly, estradiol completely inhibited LMO4-mediated apoptosis in MCF7 cells (Figure 3c ). Together, results from BMP7 and follistatin treatment experiments suggest that BMP7 is a candidate mediator of LMO4 effects in mammary epithelial cells.
To investigate whether there is a correlation between LMO4 and BMP7 levels in human breast cancer, we analysed an expression profiling study on primary breast cancers (Farmer et al., 2005) . Consistent with a previous report, showing association between high LMO4 expression and ER-negative status of tumors (Gruvberger et al., 2001 ), the average LMO4 expression level is significantly higher (2.21-fold; Po0.0001) in basal than in luminal tumors (Figure 3d ). In addition, there is a strong correlation (r ¼ 0.69) between LMO4 and BMP7 expression levels in all tumor subtypes (Figure 3e , left panel). The distribution of correlation coefficients between the expression of LMO4 and each probe set on the Affymetrix array across all breast tumors shows that BMP7 has one of the highest correlation coefficients and is significantly (Po0.0001) correlated (Figure 3e, right panel) . As expected, the top correlation coefficient is for another LMO4 probe set (Figure 3e , right panel). These results indicate that LMO4 can regulate BMP7 expression in breast cancer cells.
The BMP7 gene is a direct target of LMO4 To investigate whether LMO4 directly regulates the BMP7 gene, we cloned 1.9 kb of the proximal 5 0 flanking region of the BMP7 gene (Kawai and Sugiura, 2001) upstream of luciferase (pGL3-1.9BMP7). LMO4 was able to upregulate luciferase activity by as much as eightfold (Figure 4a , left panel). These effects were specific because LMO4 had no effect on expression of the unrelated GAL-TK-Luciferase plasmid (data not shown). Further specificity was demonstrated by testing the effect of LMO4 on 5 0 deletion mutants of the pGL3-1.9BMP7 plasmid (Figure 4a, right panel) . LMO4 was incapable of activating the expression of BMP7 reporter plasmids containing 1.2 and 0.6 kb of proximal 5 0 flanking sequence. Together, these results suggest that BMP7 may be a direct target of LMO4 and that the promoter region from À1.2 to À1.9 kb is critical for LMO4 activation of the BMP7 promoter. Interestingly, this region of the promoter has been proposed to contain a repressor element (Kawai and Sugiura, 2001) .
To test whether LMO4 binds to BMP7 promoter, we performed chromatin immunoprecipitation (ChIP) assays in MCF7-LMO4-TetOff cells in the presence and absence of doxycycline. Myc-tag antibody precipitated the BMP7 promoter in the absence of doxycycline (high LMO4) (Figure 4b , lane 6), indicating that LMO4 associates with the BMP7 promoter. These results are specific because the BMP7 promoter was not precipitated by IgG (Figure 4b , lane 5), and the Myc-tag antibody did not precipitate the U6 promoter (Figure 4b, bottom panel) . Note that since we used Myc-tag antibody, which only detects the tagged inducible protein, we did not detect the endogenous LMO4 protein in the presence of doxycycline (high LMO4) (Figure 4b, lane 4) . To test whether Clim and LMO4 can form a complex on the BMP7 promoter, we performed double ChIP assays in the MCF7-LMO4-TetOff cells, first precipitating the tagged LMO4 with a Myc antibody and then the endogenous Clim2 protein with a Clim2 antibody. Under conditions of high LMO4 expression, Clim antibody could precipitate the LMO4 complex on the BMP7 promoter (Figure 4c , lane 6), indicating that both LMO4 and Clim2 bind to the BMP7 promoter, most likely in a complex given the high-affinity interaction between these proteins (Deane et al., 2004; Ryan et al., 2006) . These results are specific because the Clim2 antibody was not able to precipitate IgG-precipitated BMP7 promoter (Figure 4c , lane 5). We next tested whether endogenous LMO4 and Clim2 can simultaneously bind to the BMP7 promoter in T47D breast cancer cells, which express relatively high levels of LMO4 (Visvader et al., 2001) . In these experiments, where we first precipitated with an LMO4 antibody and then with a Clim2 antibody, both LMO4 and Clim2 associate with the BMP7 promoter (Figure 4d, lane 3) . Together, these results suggest that a transcriptional complex containing LMO4 and Clim2 directly regulates BMP7 promoter activity.
The histone deacetylase HDAC2 is involved in regulation of BMP7 by LMO4 Since both LMO4 upregulation and expression of a DNClim molecule lead to increased expression of BMP7, LMO4 and regulation of BMP7 gene expression N Wang et al LMO4 might activate BMP7 by dismissing repressive complexes from the promoter. Therefore, we investigated whether regulated recruitment of histone deacetylases to the BMP7 promoter could account for BMP7 gene regulation by LMO4. First, we performed BMP7 ChIP assays in the MCF7-LMO4-TetOff cells, using specific antibodies against HDAC1-4. Under condition of low LMO4 expression, we clearly detected HDAC2 and HDAC3 association with the BMP7 promoter ( Figure 5a , lanes 2 and 3). While HADC3 binding was unchanged, HDAC2 binding to BMP7 promoter was decreased under conditions of high LMO4 expression (Figure 5a , lanes 6 and 7, and b, lanes 3 and 6). These findings suggested that LMO4 might upregulate the BMP7 gene by decreasing recruitment of HDAC2 to the promoter. To test this hypothesis, we performed double ChIP studies, first precipitating LMO4 and then HDAC2 in the MCF7-LMO4-TetOff cells (Figure 5b) . Consistent with the model of LMO4 regulation of HDAC2 recruitment, we found that HDAC2 was primarily recruited to the BMP7 promoter under low LMO4 levels (Figure 5b , lanes 3 and 6). As expected, only IP of cells containing high Myc-tagged LMO4 levels revealed recruitment of Clim2 to the promoter in these cells (Figure 5b , lanes 2 and 5). Further support for LMO4 involvement in HDAC2 regulation come from IP experiments where HDAC2 antibody could pull down Myc-tagged LMO4 (Figure 5c ), consistent with a recent report also showing that LMO4 can interact with HDAC2 (Singh et al., 2005) . In transfection assays, an HDAC2 shRNA and HDAC2 expression vector increased and decreased, respectively, expression of the BMP7 promoter (Figure 6a ), indicating that HDAC2 suppresses the promoter under basal conditions. Western blot analysis shows effective attenuation of HDAC2 level by HDAC2 RNAi and not by control RNAi (Supplementary Figure S9) . When the HDAC2 expression vector was co-transfected with LMO4, it blocked the LMO4-mediated stimulation of the BMP7 promoter (Figure 6a ), suggesting that decreased recruitment of HDAC2 could account for LMO4 regulation of the promoter. Together, this work has identified the BMP7 gene as a direct target of LMO4. Our findings suggest a novel mechanism for LMO-mediated stimulation of gene expression. According to this model (Figure 6b) , a LMO4 and regulation of BMP7 gene expression N Wang et al transcription complex containing LMO4 and Clim2 is sensitive to stoichiometry of components such that either overexpression or lowering of LMO4, or expression of DN-Clim, leads to decreased recruitment of HDAC2 to the promoter and activation of transcription.
Discussion
The present study extends previous studies (Wang et al., 2004; Sum et al., 2005c) by showing, in two distinct types of Cre-mediated mammary gland knockouts of LMO4, that there is decreased proliferation of mammary epithelial cells starting in early pregnancy, ultimately resulting in impaired lobuloalveolar development and mammary gland function at the end of pregnancy. Therefore, one of the roles of LMO4 is to maintain proliferation of mammary epithelial cells during early pregnancy. A top differentially expressed gene in response to LMO4 expression is BMP7, a member of the bone morphogenetic protein family, which has more than 15 mammalian members. Analysis of expression profiles of human breast cancer cases (Farmer et al., 2005) showed a highly significant correlation between LMO4 and BMP7 expression levels, indicating that BMP7 could be LMO4 responsive in human breast cancer. The link between LMO4 and BMP7 is especially intriguing because BMPs are secreted cytokines that can control multiple cellular processes, including proliferation, differentiation and apoptosis (Hogan, 1996) . By regulating BMP7, LMO4 can have pleiotrophic effects both in cancer and in development. In addition, LMO4 can modulate BMP7 signaling downstream by interacting with Smad8 (Lu et al., 2006) , one of the effecter Smads that mediates BMP7 signaling. Together, these studies suggest that LMO4 can enhance BMP7 signaling at two different levels.
Given that LMO4 appears to act as a protumorigenic factor, it is interesting that we observed a clear caspasedependent pro-apoptotic effect in response to LMO4 upregulation in normal mammary epithelial cells and in MCF-7 breast cancer cells. In addition, we found increased apoptosis of mammary epithelial cells in WAP-Cre-LMO4 fl/fl mice. These findings suggest that either an increase or a decrease in LMO4 levels, perhaps depending on context, may enhance apoptosis. This biphasic effect is similar to findings with several other effectors of apoptosis, including c-myc and ras (Chi et al., 1999; Pelengaris et al., 2002) . In addition, recent studies indicate that the relationship between cell survival and cancer is more complex than thought previously. For example, in the liver system, increased cell death is linked to hepatocarcinogenesis, possibly through compensatory proliferation (Maeda et al., 2005) . Therefore, it is possible that promotion of apoptosis may be a component of the tumor-promoting effect of LMO4. The effects of LMO4 on cell survival LMO4 and regulation of BMP7 gene expression N Wang et al may also be highly concentration-dependent. For example, we observed a U-shaped dose-response curve between LMO4 levels and Smad-mediated transcription (Lu et al., 2006) . Finally, it is likely that LMO4 effects are context-dependent; LMO4-mediated signaling to stroma and/or other neighboring cells may be important for the pro-proliferative and pro-tumorigenic effects of LMO4 upregulation in vivo. In this regard, the identification of BMP7 as a target gene of LMO4 is relevant because BMP7 has striking effects on stromal cells (Dean et al., 2004) , and it is known that growth signaling from stromal fibroblasts during mammary gland development is regulated by TGFb ligands (Cheng et al., 2005) . Like LMO4, BMP7 is highly expressed in the ductular end buds of the developing mammary gland (Sum et al., 2005a, b) , the site of active proliferation and stromal invasion of the mammary epithelium. LMO4 and BMP7 are also highly expressed in primary breast cancer (Visvader et al., 2001; Alarmo et al., 2006) and as demonstrated here, their expression is significantly correlated in human breast cancer cases. The fact that BMP7 regulates apoptosis in mammary epithelial cells in the same way as LMO4 is consistent with the idea that it mediates some of LMO4's actions. Interestingly, LMO4 and BMP7 knockout mice share common phenotypes, including early postnatal death, malformed sphenoid bones, and fusion of some ribs (Luo et al., 1995) . The strongest evidence that BMP7 acts downstream from LMO4 comes from studies showing that follistatin, a BMP5-7 blocker, can partially block the pro-apoptotic effect of LMO4 (Figure 3c) .
We have identified a novel mechanism for how LMO4 can activate transcription. The histone deacetyl transferase HDAC2 associates with the BMP7 promoter (Figure 5a and b) and suppresses its activity as demonstrated by both overexpression and loss-offunction experiments of HDAC2 (Figure 6a ). It is likely that on the BMP7 promoter HDAC2 associates with a complex containing LMO4 and Clim2. In support of this possibility, double ChIP experiments for LMO4 and HDAC2 precipitate the BMP7 promoter (Figure 5b) , and LMO4 and HDAC2 interact in solution (Figure 5c ) (Singh et al., 2005) . We propose that LMO4 interacts directly with HDAC2, recruiting it to the BMP7 promoter. When LMO4 is upregulated, HDAC2 is sequestered from the promoter, leading to transcriptional activation (Figure 6b ).
In summary, we have identified BMP7 as an LMO4-responsive gene in human breast cancer. Biochemical experiments indicate that BMP7 is a direct target gene, with LMO4 associating with its promoter and controlling transcription by regulating the recruitment of the histone deacetylase HDAC2. LMO4 and BMP7 have similar effects on proliferation and apoptosis of mammary epithelial cells, and follistatin partially blocks the effect of LMO4, suggesting that BMP7 may at least partially mediate the effects of LMO4 in mammary epithelial cells. These findings are particularly interesting in light of the fact that LMO4 is frequently overexpressed (Visvader et al., 2001) , especially in ER-negative cases, and is associated with a poor outcome (Gruvberger et al., 2001; Sum et al., 2005b) .
Materials and methods
Generation of mammary gland LMO4 knockout mice B6129-Tg(WAP-Cre)11738Mam/J and B6129-Tg(MMTVCre)4Mam/J mice (Wagner et al., 1997) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). LMO4 fl/fl mice on the C57/BL6 background were described previously (Lee et al., 2005) . We generated mice carrying mammary gland LMO4 knockouts by mating the WAP-Cre and MMTV-Cre mice with LMO4 fl/fl mice. We used published PCR primer sequences for identifying MMTV-Cre and WAP-Cre mice according to instructions from the Jackson Laboratory. PCR primers for detecting wild type, floxed and deleted LMO4 alleles are published previously (Lee et al., 2005) .
Real-time quantitative PCR analysis
Total RNA was extracted with TRIzol s (Invitrogen, Carlsbad, CA, USA) and cDNAs were generated with the High-Capacity cDNA archive kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Real-time PCR was performed with SYBR Green or commercially available TaqMan Gene Expression Assays (Applied Biosystems).
Whole-mount mammary gland preparation, histology and immunostaining The inguinal mammary glands were processed for wholemount analysis (Wang et al., 2004) . For histology, mammary glands were fixed in 10% neutral formalin overnight, paraffin embedded, and 6 mm sections were stained with hematoxylin and eosin. To evaluate mammary gland cell proliferation, sections were stained with Ki67 antibody (Novocastra, Norwell, MA, USA) at 1:1000 dilution. We quantified cell proliferation by counting 500 cells in random fields from each mouse and determined the fraction of cells stained with Ki67 antibody.
Cell proliferation and apoptosis assays Cell numbers were evaluated with the CellTiter 96 s AQueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI, USA). Apoptosis was quantified with the Cell Death Detection ELISA PLUS kit (Roche), and by Annexin V staining (Roche, Indianapolis, IN, USA; 1858777) and FACS analysis (Lu et al., 2006) .
Construction of plasmids
We generated the tetracycline-repressible LMO4 and DN-Clim expression plasmids by cloning Myc-tagged LMO4 (Sugihara et al., 1998) and DN-Clim (Wang et al., 2004) into the pTRE2hyg vector (BD Biosciences, San Jose, CA, USA).
Cell culture and generation of stable cell lines The MCF7 Tet-Off cell line was obtained from Clontech (Mountain View, CA, USA) (cat 630907) and maintained according to the vendor's recommendations. Normal HMECs were purchased from Cambrex (East Rutherford, NJ, USA), and grown according to the manufacturer's instructions. The pLNCX2 retroviral vectors were previously described (Lu et al., 2006) .
Microarray analysis
Total RNA was isolated from three distinct MCF7-LMO4-TetOff cell lines and three distinct MCF7-DN-Clim-TetOff cell lines in presence and absence of DOX after 6 days. To decrease variability, we pooled RNAs from three experiments for each of the three cell lines. RNA was labeled and hybridized to Affymetrix DNA chips.
Transient transfection reporter assays HEK293T cells were seeded into six-well plates 1 day before transfection. Luciferase reporter (1 mg) and effector plasmids (0.5 mg) were co-transfected by calcium phosphate method, and luciferase activity was measured 2 days after transfection as described (Lu et al., 2006) . All experiments were carried out at least three times, each time in triplicate.
Coimmunoprecipitation and chromatin immunoprecipitations assays Coimmunoprecipitations (Co-IPs) were performed with extracts from MCF7-LMO4-TetOff cells as described previously (Lu et al., 2006) . ChIP assays were performed according to the protocol from Upstate Cell Signaling Solutions. Details of antibodies and PCR primers are in Supplementary Information.
Detailed descriptions of Materials and methods can be found in Supplementary Information.
